For state-licensed medical cannabis businesses, the federal rescheduling of marijuana from Schedule I to Schedule III is not just a policy headline - it has direct, immediate consequences for how they file taxes. A bipartisan group of U.S. House members is now pushing the IRS and the Department of the Treasury to issue clear, actionable guidance before operators are left guessing at filing time. The urgency is real: without explicit direction from federal tax authorities, dispensaries and other cannabis businesses face genuine compliance uncertainty during what should be a clarifying moment.
What the Rescheduling Actually Changes for Operators
Section 280E of the Internal Revenue Code has long been one of the most punishing features of the federal tax framework for cannabis businesses. Under 280E, any business trafficking in Schedule I or Schedule II controlled substances is barred from deducting ordinary and necessary business expenses - rent, payroll, utilities, marketing - from its federal taxable income. For a cannabis dispensary operating on thin margins while competing with illicit markets, this is not a technicality. It has meant effective federal tax rates that can far exceed what comparable retail businesses pay.
With Acting Attorney General Todd Blanche's rescheduling order shifting state-licensed medical marijuana to Schedule III, 280E no longer applies to that segment of the market. That's a material change. Businesses operating under qualifying state medical cannabis licenses can now, in principle, claim standard business deductions. The problem, as the lawmakers' letter makes clear, is that "in principle" is doing a lot of heavy lifting right now.
The Dual-License Problem and Why It Matters
Here's where the operational complexity sits. The rescheduling order applies specifically to cannabis regulated under state medical cannabis licenses. Recreational - or adult-use - marijuana remains on Schedule I, pending further federal review. That split creates a compliance headache for a substantial portion of the industry.
Many cannabis operators hold licenses that blur those lines. The letter from Representatives Steven Horsford (D-NV), Steve Cohen (D-TN), and colleagues specifically calls out two scenarios the IRS needs to address:
- Businesses operating under a single state-issued license that covers both adult-use and medicinal cannabis activity.
- Businesses holding separate state licenses - one for adult-use, one for medical - and running both operations.
Without guidance on how to allocate costs, deductions, and credits between those two license types, operators are effectively being asked to make consequential tax decisions without a rulebook. Multi-state operators (MSOs) running vertically integrated businesses - cultivation, manufacturing, distribution, retail - face even more layered exposure here, since 280E liability compounds across every tier of the supply chain they control.
Why the Timeline Pressure Is Legitimate
The Treasury and IRS have acknowledged that guidance is forthcoming. The lawmakers' letter isn't a protest against inaction so much as a push against delay. Tax decisions don't wait for regulatory schedules. Operators are making real-time choices about payroll structuring, capital investment, and cost accounting that will be baked into returns filed months from now.
The letter also asks Treasury and IRS to loop in the Small Business Administration to help distribute guidance widely. That's a practical ask - not every licensed cannabis operator has a sophisticated tax counsel on retainer. Independent dispensary owners, particularly those in social equity licensing programs, are exactly the businesses most likely to misapply the new rules if the government's communication is slow or indirect.
What's striking here is that the ask isn't for new law. Congress isn't trying to rewrite the tax code. Reps. McCollum, Holmes Norton, Tlaib, Huffman, and García are simply pressing federal agencies to clarify what the existing change already means - which is exactly the function administrative guidance is supposed to serve.
The Broader Stakes for Cannabis Retail Finance
The financial structure of a dispensary has always been distorted by 280E. Savvy operators have historically leaned on cost of goods sold (COGS) accounting as their primary tool for minimizing federal tax exposure - since COGS remains deductible even under 280E - while watching standard business deductions disappear into the federal tax wall. That workaround has shaped everything from how operators capitalize their balance sheets to how they negotiate commercial leases.
A clean 280E exemption for medical operations changes those calculations. Operators who can now claim rent, labor, and operating costs as deductions could see meaningful reductions in effective federal tax burden - resources that could be redirected toward compliance infrastructure, inventory investment, or staff wages. To put it plainly: this isn't an accounting footnote. For operators in high-cost medical cannabis markets, it could be the difference between a viable business model and a perpetually squeezed one.
The guidance, when it arrives, will also matter to lenders, investors, and cannabis-focused CPAs who are already advising clients on how to position their books. Clarity from the IRS won't just reduce disputes - it will reduce the cost of uncertainty itself, which cannabis businesses have been absorbing for years.
